Related Experiment Videos
Is erythromycin therapy teratogenic in humans?
Bengt A J Källén1, Petra Otterblad Olausson, Bengt R Danielsson
1Tornblad Institute, Lund University, Biskospgatan 7, SE-22362 Lund, Sweden. embryol@embryol.lu.se
Reproductive Toxicology (Elmsford, N.Y.)
|May 24, 2005
Summary
Erythromycin use in early pregnancy may increase the risk of congenital malformations, particularly cardiovascular defects and pyloric stenosis, in infants. Penicillin V did not show this association.
Area of Science:
- Pharmacology
- Teratology
- Reproductive Medicine
Background:
- Previous studies suggested potential teratogenic effects of erythromycin.
- Understanding drug safety during pregnancy is crucial for public health.
Purpose of the Study:
- To investigate the association between erythromycin therapy in early pregnancy and congenital malformations.
- To compare the risk of malformations between erythromycin and penicillin V exposure.
Main Methods:
- Utilized the Swedish Medical Birth Register, collecting data from interviews on drug use in early pregnancy.
- Analyzed data from women who took erythromycin or penicillin V and their infants.
Main Results:
- Erythromycin therapy was associated with an increased risk of any congenital malformation (OR 1.24, 95% CI: 1.01-1.51).
- This increase was primarily driven by cardiovascular malformations (OR 1.92, 95% CI: 1.37-2.68).
- An elevated risk for pyloric stenosis was also indicated (RR 3.0, 95% CI: 1.1-8.5).
Conclusions:
- Erythromycin use in early pregnancy may pose a teratogenic risk, particularly for cardiovascular development.
- The mechanism may involve erythromycin's inhibition of the cardiac potassium channel (IKr) in early embryonic development.
- Further research is warranted to confirm these findings and explore underlying mechanisms.